

News Article downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009  
Read [The CNS Market Outlook to 2009](#) on BioPortfolio.com  
([http://www.bioportfolio.com/news/The\\_CNS\\_Market\\_Outlook\\_to\\_2009.html](http://www.bioportfolio.com/news/The_CNS_Market_Outlook_to_2009.html))

# The CNS Market Outlook to 2009

Thursday 1st of January 1970 1:00

## The CNS Market Outlook to 2009

The management report 'The CNS Market Outlook to 2009' provides in-depth analysis of the current growth opportunities, threats, leading players and their future prospects; it will enable you to understand the most attractive market sectors and discover what will influence competitive strategy and franchise development. As traditional markets stagnate, many major pharmaceutical companies have been slow to seize opportunities to develop markets and key growth indications. At the same time, increased pricing pressure from generic competition and limited differentiation among new medicines will see some major players facing disappointing performances and prompting strategic changes. Identify the potential growth areas within key CNS markets (Alzheimer's disease, depression, epilepsy, migraine, multiple sclerosis, pain, Parkinson's disease and schizophrenia) and formulate the most effective future strategy for your company to reduce resource wastage.

Sept 2004 248 pages PDF format

### Table of Contents

The CNS Market Outlook to 2009	
Executive Summary	14
Patient potential	14
Global market analysis	15
Global players in the CNS market	16
Development of key market segments to 2009	17
Chapter 1 Patient potential	20
Summary	20
Introduction	21
Alzheimer's disease	23
Background	23
Prevalence	24
Depression	25
Background	25
Depression and co-morbidities	26
Prevalence	28
US	28
Western Europe	29

Japan 30  
Pediatric prevalence 31  
Epilepsy 32  
Patient potential 33  
Multiple sclerosis (MS) 34  
Background 34  
Patient potential 36  
Pain 38  
Post-operative pain 39  
Cancer pain 40  
Neuropathic lower back pain 41  
HIV-related pain 42  
Fibromyalgia 42  
Arthritic pain 44  
Patient potential 44  
Schizophrenia 47  
Prevalence of schizophrenia 48  
Migraine 49  
Patient potential 50  
Parkinson's disease 51  
Patient potential 52  
Genetic factors 52  
Environmental factors 53  
Geographical differences 53  
Prevalence 53  
Chapter 2 Global market analysis 56  
Summary 56  
Migraine 57  
Rx market overview 57  
Drug analysis 59  
Other Rx drugs 63  
Epilepsy 67  
Market overview 68  
Traditional anti-convulsants 69  
Competitive overview 70  
Drug analysis 71  
Second-generation anti-convulsants 74  
Competitive overview 74  
Drug analysis 75  
Multiple Sclerosis 81  
Market overview 82  
Drug analysis 84  
Alzheimer's disease 91  
Drug analysis 93  
Depression 100  
Market overview 101  
Serotonergics 104  
Competitive overview 105  
Drug analysis 106  
TCAs 113  
Competitive overview 113  
Noradrenergics 114  
Competitive overview 114

Drug analysis 115  
MAOIs and 'Others' 118  
Competitive overview 119  
Drug analysis 119  
Parkinson's Disease 121  
Market overview 122  
Dopaminergics 124  
Competitive overview 125  
Drug analysis 125  
Dopamine agonists 127  
Competitive overview 127  
Drug analysis 128  
MAOIs 133  
Competitive overview 134  
Anticholinergics 134  
Competitive overview 134  
COMT inhibitors 135  
Competitive overview 135  
Drug analysis 136  
Schizophrenia 137  
Competitive overview 139  
Drug analysis 140  
Pain 148  
Overview 148  
Market overview 148  
NSAIDs market overview 149  
NSAID drug analysis 150  
Opioids 157  
Opioid drug analysis 158  
Chapter 3 Global players in the CNS Market 162  
Summary 162  
Introduction 163  
Pfizer 165  
Marketed products 165  
R&D compounds 166  
Asenapine 166  
Sumanitrol 167  
Indiplon 168  
CP-526,555 170  
P57 170  
PNU-170,413 171  
CNS portfolio sales forecasts and forecast revenue growth 172  
GlaxoSmithKline 173  
Marketed products 173  
R&D compounds 174  
Avandia (rosiglitazone) 175  
Talnetant 175  
353162 175  
CNS portfolio sales forecasts and forecast revenue growth 176  
Johnson & Johnson 177  
Marketed products 177  
R&D compounds 177  
CNS portfolio sales forecasts and forecast revenue growth 178

Eli Lilly 179  
Marketed products 179  
R&D compounds 180  
Cymbalta (duloxetine) 180  
CNS portfolio sales forecasts and forecast revenue growth 182  
Wyeth 183  
Marketed products 183  
R&D compounds 184  
DVS-233 184  
CCI-779 185  
SRA-333 and AAB-001 185  
CNS portfolio sales forecasts and forecast revenue growth 186  
AstraZeneca 187  
Marketed products 187  
R&D compounds 188  
Cerovive 188  
AR-A2 189  
CNS portfolio sales forecasts and forecast revenue growth 189  
Sanofi-Synthélabo 190  
Marketed products 190  
R&D compounds 191  
Xaliproden 192  
SR 58611 193  
Rimonabant 193  
Eplivanserin and osanetant 194  
Saredutant 195  
SL-65.1498 196  
CNS portfolio sales forecasts and forecast revenue growth 196  
Abbott 197  
Marketed products 197  
R&D compounds 197  
ABT-834, ABT-894 198  
CNS portfolio sales forecasts and forecast revenue growth 198  
Forest Labs 199  
Marketed products 199  
R&D compounds 200  
Acamprosate 200  
Neramexane 202  
CNS portfolio sales forecasts and forecast revenue growth 203  
Novartis 204  
Marketed products 204  
R&D compounds 205  
TCH346 205  
AMP397 205  
CNS portfolio sales forecasts and forecast revenue growth 206  
Chapter 4 Development of key CNS  
markets to 2009 208  
Summary 208  
Introduction 209  
Markets analyzed 209  
Methodology 210  
Quantifying market unmet needs 210  
Quantifying competitive intensity 210

Quantifying market attractiveness 211  
Alzheimer's disease 213  
Overview 213  
Forthcoming launches 214  
Phase II pipeline activity 215  
New products 216  
Ebixa/Namenda (memantine) 216  
Unmet needs 217  
Rating 218  
Competitive intensity 219  
Market share of current leading products in 2009 219  
Generic competition 219  
Players in 2009 220  
Market attractiveness 220  
Patient potential 220  
Antipsychotics 222  
Overview 222  
Unmet Needs 222  
Rating 224  
Competitive intensity in 2009 224  
Market share of current leading products in 2009 224  
Generic competition 224  
Late stage pipeline activity 225  
Phase II pipeline activity 225  
Players in 2009 226  
Market attractiveness 227  
Patient potential 227  
Multiple Sclerosis 228  
Overview 228  
Unmet needs 229  
Rating 230  
Competitive intensity in 2009 230  
Market share of current leading products in 2009 230  
Generic competition 231  
Late stage pipeline activity 231  
Players in 2009 232  
Market attractiveness 233  
Patient potential 233  
Pain 234  
Overview 234  
Market unmet needs 234  
Efficacy 234  
Side-effects 235  
NSAIDS 235  
Opioids 235  
Drug delivery formulations 236  
Rating 237  
Competitive intensity 237  
Market share of current leading products in 2009 237  
Generic competition 237  
Late stage pipeline activity 238  
Players in 2009 239  
Market attractiveness 240

Patient potential 240  
Comparative analysis 241  
Comparison of market unmet needs 241  
Comparison of competitive intensity in 2009 242  
Comparison of market attractiveness 243  
Summary of commercial viability 243  
Index 244  
List of Figures  
Figure 1.1: Common psychiatric conditions that are co-morbid with MDD 26  
Figure 1.2: MDD and anxiety disorders – patient population, 2003 28  
Figure 1.3: Prevalence of major indications associated with pain, 2003 39  
Figure 2.4: Market share of the leading migraine therapies, 2003 58  
Figure 2.5: Triptan formulations by brand, 2003 59  
Figure 2.6: Market share of the leading anticonvulsant therapies, 2003 69  
Figure 2.7: Market share of the leading MS therapies, 2003 83  
Figure 2.8: Market share of the leading AD therapies, 2003 92  
Figure 2.9: Historical evolution of the anti-depressants 101  
Figure 2.10: Market share of the leading MDD therapies, 2003 102  
Figure 2.11: Market share of the leading PD therapies, 2003 123  
Figure 2.12: Market share of leading Schizophrenia therapies, 2003 139  
Figure 2.13: Market share of leading Pain therapies, 2003 149  
Figure 3.14: Competitive dynamics between leading players in the global CNS market, 2002–03  
164

Click title to order: [The CNS Market Outlook to 2009](#)

To order these reports contact [peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com) or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you.

You can also order on line at: <http://www.bioportfolio.com/cgi-bin/acatalog/search.html>

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

